Affinity DataKi: 1.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 3.40nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 3.80nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 4.30nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 4.90nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 5.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 6nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 6.10nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 8.40nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 16nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 20nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 29nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 32nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 35nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 39nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 40nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 47nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 51nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 55nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 55nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 55nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 65nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 67nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 72nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 76nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 80nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 98nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 115nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 137nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 140nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 141nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 169nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 174nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 194nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 196nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 199nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 206nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 237nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 259nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 290nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 308nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 337nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 358nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 392nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 401nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 429nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 430nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 462nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 468nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair